The European Patent Office has granted a patent to the company (No. EP 3 043 814 B1 entitled "Antigen and method for production thereof") following the approval of the US-member of this patent family in 2018 (under US Patent 10,159,729 B2).
These patents cover the composition-of-matter, methods and uses of the company's novel antigen technology, strengthening Salipro Biotech's proprietary platform technologies for the discovery and development of next-generation therapeutics against challenging drug targets such as GPCRs, ion channels and transporters.
Headquartered in Stockholm, the privately held biotech has a fully-owned IP portfolio that covers the Salipro platform technology for the stabilization of membrane proteins.
"We're constantly increasing our collaborations, partnerships and licensing agreements with major pharma companies on a wide range of challenging drug targets,” said Maria Knudsen, Business Development Director at Salipro Biotech AB.
“Expanding our already strong patent portfolio further will enable us to increase the value of such collaborations for our partners as well as moving towards building our own discovery pipeline."
Jens Frauenfeld, CEO, added: "We're excited about this important milestone that provides additional protection for our core technologies. The market for therapeutic antibodies, vaccines and biologics is ever expanding. Securing these patents protects our innovative platform and further strengthens our position by supplementing our foundational and follow-up patents that have already been granted to Salipro Biotech in many countries, including US, EU, China and Japan."
To date, Salipro Biotech has signed multiple research collaborations and licensing agreements with top-tier pharma and biotech companies. In October, it entered into a collaboration and license agreement with AbCellera; and in 2020 it entered into a collaboration agreement with Germany’s DyNAbind for drug discovery against challenging membrane protein targets.